@article { author = {}, title = {Prognostic Value of a CYP2B6 Gene Polymorphism in Patients with Acute Myeloid Leukemia}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {16}, number = {11}, pages = {4583-4587}, year = {2015}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {Background: The objectives of this study aimed to detect a CYP2B6 polymorphism in de novo cases of acutemyeloid leukemia patients and identify any role in disease progression and outcome. Materials and Methods:DNA was isolated from peripheral blood of 82 newly diagnosed acute myeloid leukemia cases and the CYP2B6G15631T gene polymorphism was assayed by PCR restriction fragment length polymorphism (PCR-RFLP).Results: The frequency of the GG genotype (wild type) was 48 (58.5%) and that of the mutant type T allele was 34(41.9%). GT genotype heterozygous variants were found in 28 (34%), and TT genotype homozygous variants in6 (7.3%) cases. We found no significant association between the CYP2B6 G15631T polymorphism and completeresponse (CR) (p-value=0.768), FAB classification (p-value=0.51), cytogenetic analysis (p-value=0.673), and overallsurvival (p-value=0.325). Also, there were no significant links with early toxic death (p-value=0.92) or progressionfreesurvival (PFS) (p-value=0.245). Conclusions: Our results suggest that the CYP2B6 polymorphism has norole in disease progression, therapeutic outcome, patient free survival, early toxic death and overall survival inacute myeloid leukemia patients.}, keywords = {CYP2B6 G15631T,AML,Prognosis,PCR/RFLP}, url = {https://journal.waocp.org/article_31128.html}, eprint = {https://journal.waocp.org/article_31128_8bdd65df54edbe4400ecb44c2c661b4d.pdf} }